PharmaForce Inc. competitors

Nikhil Lalwani is a Board Member at ANI PHARMACEUTICALS INC and President/CEO at ANI PHARMACEUTICALS INC. He has worked as Chief Executive Officer at Cipla USA Inc.. Nikhil studied at Georgia Tech and The Wharton School.

Timothy Crew is a Chief Executive Officer at LANNETT CO INC and Board Member at LANNETT CO INC. He has worked as VP:Alliances & Business Development at Teva Pharmaceutical Indus Ltd, Captain at United States Army, and CEO:North America at cipla. Timothy works or has worked at BRISTOL MYERS SQUIBB CO. He attended Columbia Graduate School of Business and Pomona.

Anil D'souza is a Chief Executive Officer at TOLMAR and is based in Lincolnshire, Illinois. He has worked as President, Japan & Emerging Markets at HOSPIRA INC; First Lieutenant at Marine Corps Recruiting; and Client Manager at INTERNATIONAL BUSINESS MACHINES CORP. Anil attended Tuck School of Business at Dartmouth between 1998 and 2000, University of Chicago Committee on International Relations between 1989 and 1991, and University of Chicago between 1987 and 1991.

Arpit Patel is an Associate Director, Quality Assurance and Compliance at Aurolife Pharma LLC and Chief Executive Officer & Board Member at CorePharma LLC and is based in Dayton, New Jersey. He has worked as Quality Engineer, Quality Compliance at 29 Consulting LLC - Vascular Therapies, Inc; Quality Assurance Consultant at CorePharma LLC; and Acting Director, Quality Assurance and Compliance at Aurolife Pharma LLC. Arpit attended Fairleigh Dickinson University-Metropolitan Campus between 2007 and 2009; Gujarat University, L M College of Pharmacy; and Telnet between 2002 and 2006.

Marcy A. Bliss, Chief Executive Officer of private-equity-owned Wedgewood Pharmacy, is responsible for overall company performance. She is a member of the board of directors and works with the owners, board, and management team to set and to ensure the delivery of patient care, prescriber service, corporate vision, mission, strategy, structure, and long-term goals. The company’s brand is recognized by 99% of veterinarians in the United States. Under her leadership, in July 2018 the company acquired a significant competitor, Diamondback Drugs, in Scottsdale, Arizona, adding a second compounding pharmacy location and 180 employees. In 2020, the company acquired Wildlife Pharmaceuticals and its ZooPharm subsidiary; and opened a 503B Outsourcing Facility, Wedgewood Connect, in San Jose, California. During her tenure, Wedgewood Pharmacy has received many awards. In 2019, she was honored personally by the Gloucester County Chamber of Commerce as Businessperson of the Year. In 2017, the company received the annual Award for Excellence from the New Jersey Business & Industry Association in the Outstanding Employer category, recognizing the company’s creative and forward-looking approach to managing its workforce. In that same year, the company received the inaugural P.E.T. award from the PSI Business Symposium. The award’s acronym stands for three vital components of veterinary practice success, People, Education and Training. Wedgewood Pharmacy was recognized as the Education winner for its substantial public affairs education work with veterinarians, state and federal legislators and regulators. In 2016, the company received the fourth annual Marcum Innovator of the Year Award, which recognizes the Greater Philadelphia metropolitan area’s most innovative individuals and organizations in their fields. In 2015, the company received the Annual Award for Excellence from the New Jersey Business and Industry Association in the Business Success category, recognizing the company’s contribution to the state’s economic growth through the expansion of its business. A tireless defender of veterinary compounding and a fierce advocate for the rights of animals and pet parents, she leads the company's public affairs and issues-management programs and is frequently seen on Capitol Hill, protecting patient and prescriber access to compounded medication. She also speaks to professional groups about the compounding pharmacy profession, marketing, and public affairs. Most recently she was executive vice president of business operations and marketing for Wedgewood Pharmacy, having begun her career with the company in early 1999 as employee number eight. Over the years, she assumed positions of increasing responsibility, many with a significant emphasis on marketing, product development, and pharmacy growth. Prior to joining Wedgewood Pharmacy, she was chief marketing officer for the accounting and consulting firm, The Siegfried Group. Previously, she was a member of the staff of American Red Cross's (ARC) national office in Washington, DC, for planning, evaluation, and chapter operations and later served as communication manager for the Wilmington chapter of the ARC. In addition to her role on the board of Wedgewood Pharmacy since 2016, she serves on the board of the New Jersey Business and Industry Association; and is a member of the board of trustees of The Appel Farm Arts & Music Center (chair 2018-2020), where she is committed to supporting its mission of transforming lives through the arts. Previously, she served on the board of directors of the Tobin Foundation for the Visually Impaired. She holds a B.S. degree in Business/Marketing and Management Studies from the University of Maryland. A life-long learner, she has continued her education at Wharton Executive Education, University of Pennsylvania, Aresty Institute of Executive Education; the Hasso Plattner Institute of Design at Stanford University (Stanford, CA); and as an Executive Mastery client of Gap International.

Jim Love joined Wellpartner as President in December 2011 and was named Chief Executive Officer in April 2012. Prior to joining Wellpartner, Mr. Love had significant healthcare experience in both operations and investment banking. He spent the early part of his career in the investment banking division of Merrill Lynch & Company where he led the healthcare group and provided both strategic and financing advice to a wide range of companies including Johnson & Johnson, Hospital Corporation of America, Medco, and Biogen Idec. Mr. Love left Merrill Lynch to serve as Executive Vice President of Synetic Inc. (and its successor company Medical Manager, Inc.) a publicaly traded healthcare information technology company, where he was responsible for all finance and administrative functions. During his tenure at Synetic, Mr. Love led the efforts to raise both debt and equity capital, acquire several business, and ultimately merge the company with WebMD. After the merger with WebMD, Mr. Love returned to the investment banking business, at the Bank of Montreal, where he rebuilt the firm’s commercial and investment banking healthcare effort, and at Madison Williams and Company, where he was a senior investment banker. Mr. Love received an A.B. degree from Brown University, and a M.B.A degree from New York University.

Mr. Tabasso holds a B.A. from Cornell University, and a J.D. from Villanova University. Prior to joining KVK-Tech, Mr. Tabasso spent 16 years in private practice at a large Philadelphia law firm, where his practice focused on commercial litigation, business restructuring, and transactional work. After serving as outside counsel for many years, Mr. Tabasso joined KVK as President and CEO in August, 2013. Since that time, Mr. Tabasso’s focus has been on committing KVK to three core values: Regulatory Compliance, Safety, and Productivity. Mr. Tabasso has also dedicated KVK to strengthening its commitment to our customers and supply chain partners

George Hanford is a Chief Executive Officer at Hanford Pharmaceuticals and is based in Syracuse, New York.